Floatz logo

AT-7519M

Mantle Cell Lymphoma

NCIC Clinical Trials GroupSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

173 Active assets in the Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
Busulphan
City of Hope Medical Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

AT-7519M is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →